vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and VORNADO REALTY TRUST (VNO). Click either name above to swap in a different company.

VORNADO REALTY TRUST is the larger business by last-quarter revenue ($453.7M vs $321.1M, roughly 1.4× MADRIGAL PHARMACEUTICALS, INC.). VORNADO REALTY TRUST runs the higher net margin — 1.1% vs -18.2%, a 19.3% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -0.9%).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Vornado Realty Trust is a real estate investment trust formed in Maryland in 1982, with its primary office in New York City. The company invests in office buildings and street retail in Manhattan.

MDGL vs VNO — Head-to-Head

Bigger by revenue
VNO
VNO
1.4× larger
VNO
$453.7M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+211.7% gap
MDGL
210.8%
-0.9%
VNO
Higher net margin
VNO
VNO
19.3% more per $
VNO
1.1%
-18.2%
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MDGL
MDGL
VNO
VNO
Revenue
$321.1M
$453.7M
Net Profit
$-58.6M
$4.9M
Gross Margin
Operating Margin
-18.6%
2.8%
Net Margin
-18.2%
1.1%
Revenue YoY
210.8%
-0.9%
Net Profit YoY
1.4%
-14.7%
EPS (diluted)
$-2.55
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
VNO
VNO
Q4 25
$321.1M
$453.7M
Q3 25
$287.3M
$453.7M
Q2 25
$212.8M
$441.4M
Q1 25
$137.3M
$461.6M
Q4 24
$103.3M
$457.8M
Q3 24
$62.2M
$443.3M
Q2 24
$450.3M
Q1 24
$0
$436.4M
Net Profit
MDGL
MDGL
VNO
VNO
Q4 25
$-58.6M
$4.9M
Q3 25
$-114.2M
$27.1M
Q2 25
$-42.3M
$759.3M
Q1 25
$-73.2M
$102.4M
Q4 24
$-59.4M
$5.8M
Q3 24
$-107.0M
$-3.6M
Q2 24
$50.8M
Q1 24
$-147.5M
$6.5M
Gross Margin
MDGL
MDGL
VNO
VNO
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
MDGL
MDGL
VNO
VNO
Q4 25
-18.6%
2.8%
Q3 25
-39.7%
3.0%
Q2 25
-22.2%
Q1 25
-57.8%
23.2%
Q4 24
-64.8%
2.5%
Q3 24
-187.1%
-3.3%
Q2 24
10.1%
Q1 24
0.1%
Net Margin
MDGL
MDGL
VNO
VNO
Q4 25
-18.2%
1.1%
Q3 25
-39.8%
6.0%
Q2 25
-19.9%
172.0%
Q1 25
-53.4%
22.2%
Q4 24
-57.5%
1.3%
Q3 24
-172.0%
-0.8%
Q2 24
11.3%
Q1 24
1.5%
EPS (diluted)
MDGL
MDGL
VNO
VNO
Q4 25
$-2.55
$0.01
Q3 25
$-5.08
$0.06
Q2 25
$-1.90
$3.70
Q1 25
$-3.32
$0.43
Q4 24
$-2.50
$0.01
Q3 24
$-4.92
$-0.10
Q2 24
$0.18
Q1 24
$-7.38
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
VNO
VNO
Cash + ST InvestmentsLiquidity on hand
$198.7M
$840.9M
Total DebtLower is stronger
$339.9M
$2.3B
Stockholders' EquityBook value
$602.7M
$6.0B
Total Assets
$1.3B
$15.5B
Debt / EquityLower = less leverage
0.56×
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
VNO
VNO
Q4 25
$198.7M
$840.9M
Q3 25
$295.7M
$1.0B
Q2 25
$186.2M
$1.2B
Q1 25
$183.6M
$568.9M
Q4 24
$100.0M
$733.9M
Q3 24
$232.7M
$783.6M
Q2 24
$872.6M
Q1 24
$622.5M
$892.7M
Total Debt
MDGL
MDGL
VNO
VNO
Q4 25
$339.9M
$2.3B
Q3 25
$339.8M
$2.3B
Q2 25
$118.4M
$2.1B
Q1 25
$118.0M
$2.1B
Q4 24
$117.6M
$2.6B
Q3 24
$117.1M
$2.6B
Q2 24
$2.6B
Q1 24
$116.1M
$2.6B
Stockholders' Equity
MDGL
MDGL
VNO
VNO
Q4 25
$602.7M
$6.0B
Q3 25
$625.7M
$6.1B
Q2 25
$696.0M
$6.1B
Q1 25
$710.6M
$5.3B
Q4 24
$754.4M
$5.2B
Q3 24
$777.2M
$5.3B
Q2 24
$5.6B
Q1 24
$850.8M
$5.5B
Total Assets
MDGL
MDGL
VNO
VNO
Q4 25
$1.3B
$15.5B
Q3 25
$1.4B
$15.7B
Q2 25
$1.0B
$15.6B
Q1 25
$996.6M
$15.6B
Q4 24
$1.0B
$16.0B
Q3 24
$1.1B
$16.1B
Q2 24
$16.2B
Q1 24
$1.1B
$16.2B
Debt / Equity
MDGL
MDGL
VNO
VNO
Q4 25
0.56×
0.38×
Q3 25
0.54×
0.37×
Q2 25
0.17×
0.35×
Q1 25
0.17×
0.40×
Q4 24
0.16×
0.50×
Q3 24
0.15×
0.49×
Q2 24
0.46×
Q1 24
0.14×
0.46×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
VNO
VNO
Operating Cash FlowLast quarter
$-133.5M
$1.3B
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
256.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
VNO
VNO
Q4 25
$-133.5M
$1.3B
Q3 25
$79.8M
$33.2M
Q2 25
$-47.1M
$1.0B
Q1 25
$-88.9M
$52.0M
Q4 24
$-104.5M
$537.7M
Q3 24
$-67.0M
$105.4M
Q2 24
$194.7M
Q1 24
$-149.2M
$31.5M
Free Cash Flow
MDGL
MDGL
VNO
VNO
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
Q1 24
$-149.5M
FCF Margin
MDGL
MDGL
VNO
VNO
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Q1 24
Capex Intensity
MDGL
MDGL
VNO
VNO
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Q1 24
Cash Conversion
MDGL
MDGL
VNO
VNO
Q4 25
256.08×
Q3 25
1.22×
Q2 25
1.35×
Q1 25
0.51×
Q4 24
93.39×
Q3 24
Q2 24
3.83×
Q1 24
4.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

VNO
VNO

New York Segment$374.8M83%
Building Maintenance Service$41.2M9%
Other$27.7M6%
Tenant Services$11.1M2%
Management And Leasing Fees$2.6M1%

Related Comparisons